Covered recipient · General Payments record
GWEN WEBSTER
General Payments · PY2018–2024
$3,166.80
- Reported across 55 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,200.00 | 6 |
| Food and Beverage | $131.91 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MIMEDX Group, Inc. | $2,200.00 | 6 |
| Astellas Pharma US Inc | $36.25 | 2 |
| MILLICENT US INC | $18.94 | 1 |
| PFIZER INC. | $17.82 | 1 |
| Organon LLC | $17.63 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $15.64 | 1 |
| Exeltis, USA Inc. | $14.41 | 1 |
| MAYNE PHARMA COMMERCIAL LLC | $11.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $20.03 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139424159 | CMS |
| Astellas Pharma US Inc | $16.22 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139424233 | CMS |
| Exeltis, USA Inc. | $14.41 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150007222 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $15.64 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146794700 | CMS |
| MAYNE PHARMA COMMERCIAL LLC | $11.22 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154679973 | CMS |
| MILLICENT US INC | $18.94 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150913175 | CMS |
| MIMEDX Group, Inc. | $600.00 | 04/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140271720 | CMS |
| MIMEDX Group, Inc. | $600.00 | 05/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140271722 | CMS |
| MIMEDX Group, Inc. | $200.00 | 06/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140271724 | CMS |
| MIMEDX Group, Inc. | $200.00 | 07/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140271726 | CMS |
| MIMEDX Group, Inc. | $200.00 | 10/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140271728 | CMS |
| MIMEDX Group, Inc. | $400.00 | 12/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1140271730 | CMS |
| Organon Llc | $17.63 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136221638 | CMS |
| PFIZER INC. | $17.82 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131848570 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.